Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract CancerDino Bekric(Paracelsus Medical University), Christian Mayr(Paracelsus Medical University)CancersMarch 2, 202310.3390/cancers15051569Cited by 17SaveCiteExport RISWatch citationsRelated PapersThe BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells|Oncotarget|2015|42The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells|PLoS ONE|2024|7